Panel Discussion | Atherosclerosis Therapeutic Options and Management - What is Promising?

Sunday, March 8, 2026

5:15 PM - 5:35 PM EST

Location: Monroe

Moderator(s)

Charles German, MD, MS, FAHA, FASPC

Assistant Professor
Georgetown University

Disclosure(s): No financial relationships to disclose
Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI

Professor of Cardiology and Population Health Science and Policy, Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials; Director of Women’s Heart and Vascular Center at Mount Sinai Heart
Icahn School of Medicine at Mount Sinai, New York
New York, New York, United States

Disclosure(s): Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AMA - JAMA Cardiology (Associate Editor), ACC (Vice President, BOT Member, SC Member CTR Program): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Elixir Medical, Stel, ControlRad (spouse): Stock Options [in privately held companies] (Ongoing); Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ;: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director): No Fees (Ongoing)
Jean-Claude Tardif, MD

Director of Research Center
Montreal Heart Institute
Montreal, Quebec, Canada

Disclosure(s): Boehringer-Ingelheim: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Terminated); DalCor Pharmaceuticals: Grant/Research Support (Ongoing), Stock Options [in privately held companies] (Ongoing); Merck: Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); Novo-Nordisk: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)

Panel Discussant(s)

Tiziana Claudia Aranzulla, MD, MSc

Interventional cardiology
A.O. Ordine Mauriziano di Torino
Turin, Italy

Disclosure(s): No financial relationships to disclose
MB

Marc P. Bonaca, MD

Disclosure information not submitted.
David Erlinge, MD, PhD

Professor, Consultant Interventional Cardiology
Lund University
Lund, Sweden

Disclosure(s): chiesi, bracco: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); kaminari, medical: Consulting Fees (e.g., advisory boards) (Ongoing)
Paul A. Gurbel, MD, FSCAI

Director
Sinai Center for Thrombosis Research and Drug Development
Baltimore, Maryland, United States

Disclosure information not submitted.
Michael Mahmoudi, MD

Professor of Interventional Cardiology
University Hospital Southampton NHS FT
Southampton, England, United Kingdom

Disclosure(s): No financial relationships to disclose
Robert S. Rosenson, MD

Director of Metabolism and Lipids
Mount Sinai Health System
New York, New York, United States

Disclosure information not submitted.
Scott W. Shurmur, MD

Chair, Internal Medicine; Interventional PD
Texas Tech Health Sciences Center, Lubbock
Lubbock, Texas, United States

Disclosure(s): No financial relationships to disclose
Ori Waksman, MD

Interventional Cardiology Fellow
Medstar Washington Hospital Center

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Charles German, MD, MS, FAHA, FASPC: No financial relationships to disclose

Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, MSCAI: Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AMA - JAMA Cardiology (Associate Editor), ACC (Vice President, BOT Member, SC Member CTR Program): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Elixir Medical, Stel, ControlRad (spouse): Stock Options [in privately held companies] (Ongoing); Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ;: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); SCAI (Women in Innovations Committee Member), Faculty Cardiovascular Research Foundation (CRF), Women as One (Founding Director): No Fees (Ongoing)

Jean-Claude Tardif, MD: Boehringer-Ingelheim: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Terminated); DalCor Pharmaceuticals: Grant/Research Support (Ongoing), Stock Options [in privately held companies] (Ongoing); Merck: Grant/Research Support (Ongoing); Novartis: Grant/Research Support (Ongoing); Novo-Nordisk: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)

Tiziana Claudia Aranzulla, MD, MSc: No financial relationships to disclose

David Erlinge, MD, PhD: chiesi, bracco: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); kaminari, medical: Consulting Fees (e.g., advisory boards) (Ongoing)

Michael Mahmoudi, MD: No financial relationships to disclose

Scott W. Shurmur, MD: No financial relationships to disclose

Ori Waksman, MD: No financial relationships to disclose